Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-04-04

Clinical Trial Update: Study of Tamibarotene in Patients With ADPKD [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating tamibarotene for Autosomal Dominant Polycystic Kidney Disease (ADPKD) is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tamibarotene (tamibarotene)

Snippet

Sponsor: Rege Nephro Co., Ltd. | Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 2 | Status: ACTIVE_NOT_RECRUITING